Anelixis Therapeutics was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development
Institute (ALSTDI, www.als.net), a nonprofit biotechnology
organization dedicated to developing effective treatments for ALS.
Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts
with a portfolio focused on immune modulatory drugs for neurodegenerative diseases with a focus on
amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD). Anelixis Therapeutics is committed
to advancing treatments that will have a meaningful impact on the lives of patients by helping them
battle back their disease progression.
Anelixis Therapeutics' lead molecule, AT-1501, is a monoclonal antibody targeting CD40-ligand that
was licensed from ALS TDI. In preclinical studies, it was demonstrated by ALS TDI blocking CD40LG
signaling slowed down disease progression, improved survival, and improved muscle function. These
landmark studies identified the costimulatory pathway playing a critical role in neurodegeneration.
These studies are discussed in greater length here.
Anelixis Therapeutics has assembled an expert
clinical advisory team and consulting team. The company
has developed a cell line and manufacturing process to develop AT-1501. The team has completed IND
enabling toxicology studies in non-human primates and intends to file an IND for first in human
studies in early 2018.
Anelixis Therapeutics is led by a management team with more than 20 years of experience driving
potential treatments through the life cycle of development at major biotechnology and pharmaceutical
companies. The company has received on-going philanthropic support from ALS TDI as well as earned
peer-reviewed grants from the ALS Association, ALS Finding a Cure Foundation, ALS ONE and the
Congressionally Directed Medical Research Program for ALS operated by the Department of Defense. The
Anelixis Therapeutics team has put together the necessary plans to begin clinical trials of AT-1501
in 2018 while seeking additional partnerships to drive the development of AT-1501 and other
costimulatory targeting antibodies forward.
Contact us for more information